Who Should Receive an Allogeneic Transplant in First Complete Remission?

first complete remission versus other- than- first complete remission in acute myelogenous leukemia with allogeneic hematopoietic stem cell transplantation

introduction: the traditional goal of the treatment of acute myelogenous leukemia is to produce and maintain a complete remission (cr).the difference in survival time was entirely attributable to the duration of time spent in cr .in this study, the outcome of aml patients with allogeneic hsct in cr1 versus other than cr1 was compared. patients and methods: since march 1991 until november 2008, ...

Should an undocumented immigrant receive a heart transplant?

Who should receive bone mineral density testing?

Evidence A study of 860 postmenopausal Asian women examined 11 risk factors to predict osteoporosis1: • Multiple risk factors had minimal value over age and weight alone. • The OST was developed based on weight and age. Eight systematic reviews were conducted from 2007 to 2015, with up to 108 studies and 208 738 patients evaluating more than 9 tools to assess the risk of osteoporosis or fractur...

CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.

The appropriate timing of bone marrow transplantation (BMT) for adults with acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL) is controversial. Although allogeneic transplantation results in a lower risk of disease recurrence than intensive chemotherapy alone, overall outcome following BMT may not be improved due to the higher incidence of therapy-related fatal complicatio...

Allogeneic bone marrow transplantation for high-risk acute lymphoblastic leukemia during first complete remission.

Fifty-three patients with high-risk acute lymphoblastic leukemia (ALL) under age 50 with a histocompatible sibling donor received high-dose radiochemotherapy followed by allogeneic bone marrow transplantation (BMT). The high-risk factors used to identify the patients were: white blood cell count at initial presentation, cytogenetic abnormalities, age, extramedullary leukemic infiltration, and t...